日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma

c-MYC表达和成熟表型与多发性骨髓瘤患者在来那度胺-地塞米松方案中加入伊沙佐米后获得的疗效相关。

Di Bacco, Alessandra; Bahlis, Nizar J; Munshi, Nikhil C; Avet-Loiseau, Hervé; Masszi, Tamás; Viterbo, Luísa; Pour, Ludek; Ganly, Peter; Cavo, Michele; Langer, Christian; Kumar, Shaji K; Rajkumar, S Vincent; Keats, Jonathan J; Berg, Deborah; Lin, Jianchang; Li, Bin; Badola, Sunita; Shen, Lei; Zhang, Jacob; Esseltine, Dixie-Lee; Luptakova, Katarina; van de Velde, Helgi; Richardson, Paul G; Moreau, Philippe

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

复发/难治性多发性骨髓瘤患者接受伊沙佐米联合来那度胺/地塞米松治疗后不良事件的管理

Kumar, Shaji; Moreau, Philippe; Hari, Parameswaran; Mateos, Maria-Victoria; Ludwig, Heinz; Shustik, Chaim; Masszi, Tamas; Spencer, Andrew; Hájek, Roman; Romeril, Kenneth; Avivi, Irit; Liberati, Anna M; Minnema, Monique C; Einsele, Hermann; Lonial, Sagar; Berg, Deborah; Lin, Jianchang; Gupta, Neeraj; Esseltine, Dixie-Lee; Richardson, Paul G

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

一项对参与硼替佐米治疗多发性骨髓瘤的 II/III 期临床试验的 3954 例患者的回顾性分析:旨在为蛋白酶体抑制剂在多发性骨髓瘤治疗中的心脏安全性提供基准

Laubach, Jacob P; Moslehi, Javid J; Francis, Sanjeev A; San Miguel, Jesús F; Sonneveld, Pieter; Orlowski, Robert Z; Moreau, Philippe; Rosiñol, Laura; Faber, Edward A Jr; Voorhees, Peter; Mateos, Maria-Victoria; Marquez, Loreta; Feng, Huaibao; Desai, Avinash; van de Velde, Helgi; Elliott, Jennifer; Shi, Hongliang; Dow, Edward; Jobanputra, Nishith; Esseltine, Dixie-Lee; Niculescu, Liviu; Anderson, Kenneth C; Lonial, Sagar; Richardson, Paul G

The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials

基线特征和疾病分期对多发性骨髓瘤患者健康相关生活质量的影响:来自六项随机对照试验的结果

Robinson, Don Jr; Esseltine, Dixie-Lee; Regnault, Antoine; Meunier, Juliette; Liu, Kevin; van de Velde, Helgi

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

伊沙佐米联合来那度胺-地塞米松治疗亚洲复发/难治性多发性骨髓瘤患者的药代动力学和安全性:一项1期研究

Gupta, Neeraj; Goh, Yeow Tee; Min, Chang-Ki; Lee, Jae Hoon; Kim, Kihyun; Wong, Raymond S M; Chim, Chor Sang; Hanley, Michael J; Yang, Huyuan; Venkatakrishnan, Karthik; Hui, Ai-Min; Esseltine, Dixie-Lee; Chng, Wee Joo

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study

复发性多发性骨髓瘤患者皮下注射与静脉注射硼替佐米的疗效比较:MMY-3021 III期研究中肾功能不全患者的亚组分析

Moreau, Philippe; Pylypenko, Halyna; Grosicki, Sebastian; Karamanesht, Ievgenii; Leleu, Xavier; Rekhtman, Grigoriy; Masliak, Zvenyslava; Robak, Pawel; Esseltine, Dixie-Lee; Feng, Huaibao; Deraedt, William; van de Velde, Helgi; Arnulf, Bertrand

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

在既往未接受治疗且不适合接受高剂量治疗的多发性骨髓瘤患者中,三种不同的硼替佐米-美法仑-泼尼松方案的硼替佐米累积剂量、疗效和耐受性

Mateos, María-Victoria; Bringhen, Sara; Richardson, Paul G; Lahuerta, Juan Jose; Larocca, Alessandra; Oriol, Albert; Boccadoro, Mario; García-Sanz, Ramón; Di Raimondo, Francesco; Esseltine, Dixie-Lee; van de Velde, Helgi; Desai, Avinash; Londhe, Anil; San Miguel, Jesús F; Palumbo, Antonio

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

在接受利妥昔单抗治疗的高危、复发、利妥昔单抗初治或利妥昔单抗敏感的滤泡性淋巴瘤患者中,硼替佐米联合利妥昔单抗与单药利妥昔单抗的疗效比较:一项随机3期试验的亚组分析

Zinzani, Pier Luigi; Khuageva, Nuriet K; Wang, Huaqing; Garicochea, Bernardo; Walewski, Jan; Van Hoof, Achiel; Soubeyran, Pierre; Caballero, Dolores; Buckstein, Rena; Esseltine, Dixie-Lee; Theocharous, Panteli; Enny, Christopher; Zhu, Eugene; Elsayed, Yusri A; Coiffier, Bertrand

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

对接受硼替佐米或地塞米松治疗的复发性多发性骨髓瘤患者的20S蛋白酶体β亚基基因进行序列分析

Lichter, David I; Danaee, Hadi; Pickard, Michael D; Tayber, Olga; Sintchak, Michael; Shi, Hongliang; Richardson, Paul G; Cavenagh, Jamie; Bladé, Joan; Façon, Thierry; Niesvizky, Ruben; Alsina, Melissa; Dalton, William; Sonneveld, Pieter; Lonial, Sagar; van de Velde, Helgi; Ricci, Deborah; Esseltine, Dixie-Lee; Trepicchio, William L; Mulligan, George; Anderson, Kenneth C

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

一项多中心、I期、剂量递增试验,评估来那度胺联合硼替佐米治疗复发性和复发/难治性多发性骨髓瘤的疗效

Richardson, Paul G; Weller, Edie; Jagannath, Sundar; Avigan, David E; Alsina, Melissa; Schlossman, Robert L; Mazumder, Amitabha; Munshi, Nikhil C; Ghobrial, Irene M; Doss, Deborah; Warren, Diane L; Lunde, Laura E; McKenney, Mary; Delaney, Carol; Mitsiades, Constantine S; Hideshima, Teru; Dalton, William; Knight, Robert; Esseltine, Dixie-Lee; Anderson, Kenneth C